|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Stock based compensation | |||||
| Decrease in allowance for credit losses | |||||
| Depreciation and amortization | |||||
| Amortization of right of use assets | |||||
| Amortization of debt discount | |||||
| Write-down of licensed devices | |||||
| Inventory reserve charge | |||||
| Increase in provision for credit losses | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Inventories | |||||
| Prepaid expenses and other assets | |||||
| Accounts payable | |||||
| Accrued expense and other current liabilities | |||||
| Operating lease liabilities | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchase of property and equipment | |||||
| Purchase of marketable securities | |||||
| Sale (purchase) of marketable securities | |||||
| Net cash provided by (used in) investing activities | |||||
| Cash flows from financing activities: | |||||
| Sale of common stock and warrants | |||||
| Financing fees | |||||
| Issuance of long-term debt | |||||
| Debt issuance costs | |||||
| Equity issuance costs | |||||
| Proceeds from exercise of options | |||||
| Proceeds from exercise of warrants | |||||
| Net cash provided by financing activities | |||||
| Effect of changes in exchange rates on cash and cash equivalents | |||||
| Net decrease in cash and cash equivalents | |||||
| Cash and cash equivalents – beginning of year | |||||
| Cash and cash equivalents – end of year | |||||
| Supplemental cash flows disclosures: | |||||
| Income taxes paid | |||||
| Proceeds from sale of state net operating losses | |||||
| Interest paid | |||||
| Insurance premium financing | |||||
| Accounts payable settled through common stock and warrants | |||||
| Accounts payable settled through the exercise of warrants | |||||
| Right-of-use asset and operating lease liability | |||||
| Supplemental schedule of noncash activity: | |||||
| Insurance premium financing | |||||
| Accounts payable settled through common stock and warrants | |||||
| Accounts payable settled through the exercise of warrants | |||||
| Non-cash debt issuance costs | |||||
| Shares issued in connection with Avenue loan | |||||
| Accrued purchases of property and equipment | |||||
| Right-of-use asset and operating lease liability | |||||
Loading...